A1 The CIIE represents an opportunity for companies to foster and enhance key partnerships. It also offers a unique communication platform, where we can help build public awareness and education about diabetes as well as other serious chronic diseases.

During the past five years, we have invested in China four times to further deepen our presence across the full value chain. We showcased 18 innovative medicines and 10 injection devices at the expo. We hope to leverage the CIIE to further enhance public awareness of diseases to improve health awareness and disease management skills. We look forward to sharing our latest innovations and R&D focuses across different disease areas including diabetes, obesity, hemophilia and growth disorders.

A2 Despite the uncertainties in the global economy and the impact of COVID-19, the fifth CIIE has been held as scheduled. Serving as a window to the Chinese market, the CIIE demonstrates China's commitment to expanding and promoting inclusive development.

A3 The Chinese economy has maintained positive growth despite the pandemic's impact. We believe China will continue to be a strong economy in the world, and provide sustainable development opportunities across industries.

A4 The Chinese government has elevated people's health as a national development strategy. It has set ambitious goals of forging a comprehensive and full lifecycle healthcare system in its Healthy China 2030 plan and designed concrete measures for the prevention and management of chronic diseases including diabetes and obesity.

As Chinese healthcare reforms continuously deepen, we hope to accelerate innovation and achieve simultaneous clinical research in China and globally, so that patients in China can benefit from our innovative medicines together with those in other countries and regions.

A5 Over the past decades, China has made continuous achievements in opening-up and efforts to optimize the business environment. Novo Nordisk has continuously played an active role in, progressed alongside and made contributions to it.

We hope for continued measures to expand high-level opening-up and optimize the business environment in the Chinese market. We will continue to conduct our business activities in a financially, socially and environmentally responsible way. Novo Nordisk is aspiring to grow together with China, increasing investment and accelerating innovation.